Success in Drug Development By Rethinking Biotech

Pergamum is developing peptide-based products in dermatology, wound healing and anti-infection.

Pergamum is a clinical-stage biopharmaceutical company developing state-of-the-art products, based on therapeutic peptides, for local application in dermatology, wound healing and anti-infection.

The current development pipeline includes three lead APIs. Pergamum has five main programs, four of which are in clinical development. Two of these are targeting skin infections (atopic dermatitis) and external otitis. The other two programs are aimed at the prevention of post-surgical adhesions following flexor tendon repair surgery, and broader orthopedic surgery procedures as an extension indication. Another IND-stage program, based on a new therapeutic approach to promote healing of chronic wounds, is planned to enter clinical studies during this year.

Pergamum estimates its products have a combined peak sales potential of more than EUR 1.5 billion. Excellent potential exists for realizing a good return on investment. The company expects to achieve clinical proof of concept in up to five of its programs by the end of 2013. In the completed Phase I/II for DPK-060 in skin infections (atopic dermatitis) the primary endpoint was successfully met. In the ongoing Phase II study for PXL01 in prevention of post-surgical adhesions following flexor tendon repair surgery, data on the primary efficacy endpoint are expected in Q1 of 2012.

Pergamum has developed a unique business model that combines leading-edge program management with efficient drug and business development. This approach is designed to increase the success rate of drug development programs and minimize time-to-market. The model also enables Pergamum to pursue multiple exit and partnering opportunities, and to improve return on investment.